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Abstract 
In a previous commentary in INNOVATIONS in pharmacy, the question was raised as to the questions legislators should ask for the 
licensing of medical marijuana dispensaries. The case was made that if dispensaries accept they have a duty of care then they should 
be required to monitor patients over the course of their treatment with botanical cannabis, including hemp based product, to evaluate 
the response of patients to therapy. One option would be for individual dispensaries (or owners of multiple licenses and dispensary 
locations) to adopt a registry format and implement an on-line reporting system by registry staff and patients for the conditions being 
treated. Unfortunately, under present legislative rules for dispensaries there is no incentive for dispensaries to make the necessary 
investment. It is also unlikely that legislators would be prepared to mandate a registry requirement. The purpose of this commentary 
is to offer an alternative solution. Rather than dispensary specific registries, a state-wide low cost registry is proposed where 
dispensaries are required to log in and track patients with specific conditions. In the case of severe pain, a dispensary would log in 
patients presenting with this condition and the patient tracked over their course of treatment. A further advantage with a statewide 
registry is that if a patient visits a different dispensary they can still be tracked as they would be identified by their marijuana card 
number. The ability to track patients by condition, while still resident in a state, would not only minimize the issue of incomplete records, 
but would provide a comprehensive, research quality framework for evaluating claims for botanical cannabis. This could then provide 
feedback to legislators and establish a robust basis for rule making.  
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Introduction 
Do medical marijuana dispensaries have a duty of care to their 
patients? As noted in previous commentaries in INNOVATIONS 
in Pharmacy, if we accept the proposition that an approved 
medical marijuana dispensary is a healthcare provider, then it 
is under a reasonable obligation to ensure that the focus is on 
achieving the best possible clinical outcomes while at the same 
time endeavoring to minimize patient harms 1 2 3. The notion of 
duty of care also implies that, in the delivery of care, the 
provider is obliged to attempt to ensure than the care is 
appropriate, that it is monitored and reviewed against targets 
set for the patient, and that the outcomes achieved are 
consistent with best clinical practice.  Indeed, the case was 
made that a major oversight in approving the establishment of 
medical marijuana programs through commercially and not-
for-profit operated dispensaries is the failure to put   in place   
standards for the monitoring and reporting of outcomes. It was 
pointed out that the evidence base is limited for the range of 
dosing options, administrative routes and conditions treated.  
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The concern is that the ease that patients have in obtaining 
medical marijuana certification in many states means that a 
medical marijuana program may be, in effect, little different 
from a recreational program. Dispensaries understandably 
focus on sales and returns to investors with scant attention 
given to tracking and reporting outcomes across the range of 
conditions and symptoms presented.  While this no doubt 
appeals to investors in reducing administration costs, it makes 
it virtually impossible to deliver the appropriate and 
coordinated level of care that patients should expect. 
 
The solution proposed in one of the previous commentaries 
was to require, as part of the licensing process, that 
dispensaries meet certain reporting standards in respect of 
conditions treated. This, it was suggested, could be 
accomplished with dispensaries required to invest in a registry 
to track patients.  
 
On reflection, there are a number of potential obstacles to a 
dispensary adopting a registry platform. Among these are: (i) it 
is unlikely state legislatures would make adoption of a registry 
format a condition of licensing; (ii) without a legislative 
requirement, there is no necessary incentive for dispensaries to 
invest in a registry; and (iii) as states allow patients to shop for 
their botanical cannabis product at different dispensaries, there 
is the risk of incomplete records. Indeed, even if a dispensary 
was prepared to invest in a registry, the risk is one of losing 
customers. Patients may see the reporting as burdensome and 
an invasion of privacy (even with HIPAA standards) and move 
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their business to a ‘registry-free’ dispensary.  In short, a registry 
model that is appropriate for a physician practice where 
patients have a longer term association and where there is the 
prospect of additional practice revenue through subscribing to 
a registry (as noted in previous commentaries for chronic pain 
and behavioral health), may not be as appropriate in botanical 
cannabis 4 5 .  
  
Unfortunately, this still leaves the question of the limited 
evidence base for botanical cannabis and the failure of 
legislators to recognize that they are sanctioning botanical 
cannabis for conditions where the risk/benefit ratio is 
unknown. Indeed, recent large scale evaluations of the extent 
to which THC/CBD product characteristics offer symptom relief 
point to the lack of consensus on the risk/benefit ratios of THC 
versus CBD. In the recently reported study by Stith et al using 
mobile device software to evaluate real time effects, the 
authors concluded that across product characteristics, dried 
flower was the most commonly used and offered greater 
symptom relief that other types of products 6. Further, among 
product characteristics ‘only higher THC levels were 
independently associated with greater symptom relief and the 
presence of negative and positive side effects’ while ‘CBD 
potency levels were generally not associated with significant 
symptom changes or experienced side effects’.  While the 
authors acknowledge the limitations, including selection bias, 
in their data and the lack of cross-referencing to clinical 
assessments (which the proposed registry structure 
overcomes), their results amplify the need for studies to 
address the impact of botanical cannabis in real world treating 
environments. As the authors conclude, there is a need for 
‘innovative strategies such as the use of mobile technology for 
measuring the multidimensional relationships between 
cannabis product characteristics, patient health conditions, 
perceived symptom relief, and side effect manifestation’. 
 
Dispensary and State Registries 
Ideally, there should be a mechanism in place that facilitates 
the adoption of a registry platform to evaluate the response to 
botanical cannabis. One approach, as noted above and in 
previous commentaries is for a dispensary owner to recognize 
not only that they have an implicit duty of care in evaluating 
outcomes of therapy but that, in what has become a highly 
competitive market in most states to acquire a dispensary 
license, the ability by applicants to differentiate themselves 
may resonate with state agencies. A commitment to a registry 
model may be seen, therefore, not only as a commitment to a 
duty of care but also recognition that it is important to improve 
the botanical cannabis evidence base. More to the point 
perhaps, committing to a registry would also show that the 
dispensary recognizes the need to provide feedback to 
providers who have recommended botanical cannabis as a 
therapy option. A registry which captures response to therapy 
utilizing validated outcomes instruments offers the opportunity 
to provide regular reports to providers so that a pain specialist, 
for example, can track response to therapy. A particular 
application here would be in assessing the risk/benefit ratio of 
botanical cannabis compared to opioids. The more comfortable 
pain specialists and primary care providers are with particular 
cannabis products and dosing regimens, the more willing they 
may be to consider, for example, botanical cannabis as a viable, 
evidence based adoption in the medium and long terms 
treatment of chronic pain. The provider, to extend the example, 
may require the patient to limit their choice of product to 
flowers with a known THC/CBD ratio, where the dispensary 
initiates therapy at a ‘minimum’ dose and on successive visits 
titrating the product to achieve a clinically meaningful 
response. 
 
These arguments apply, of course, to more than just severe or 
chronic pain, which is the condition treated by 75-85% of 
patients at dispensaries. As detailed in the registry design 
described in a previous commentary the same arguments apply 
in the range of conditions typically treated (and mandated by 
state legislatures): persistent muscle spasms, severe nausea, 
post-traumatic stress disorder and seizures. In each case it is 
possible to track response to therapy through on-line patient 
self-reports, with product characteristic and dosing information 
supplied by the dispensary. A key point is the interaction 
between the provider and the dispensary to achieve and 
monitor a therapeutically meaningful response. If that is not 
achieved in an agreed timeframe then alternative interventions 
may be considered, to include polytherapy with a specific 
THC/CBD product. 
 
The adoption of a state-level registry model would provide a 
complementary data source to individual dispensary registries. 
They key assumption here, of course, is how willing state 
authorities would be to facilitating a state-level registry model. 
The model proposed here would be one established as a stand-
alone commercial product. It would sit alongside the 
established software systems in place for dispensaries to report 
to state health authorities and requirements for adverse event 
reporting and annual dispensary audits to maintain a license. 
Access would be through a web-based portal with reporting by 
both dispensary staff and patients. The structure would be little 
different from that proposed for the stand-alone dispensary 
registry. The key difference is the requirements for all 
dispensaries in the state to enroll patients who had specific 
medical conditions. At present, medical marijuana access, for 
those states with an integrated record system, is through 
conditions mandated by the legislature. A list that continues to 
expand through petitions from interested groups and 
associated bills passed by the legislature to approve access. 
 
A state level registry would capture all conditions mandated by 
the legislature and provide a series of reports that patients 
completed specific to each mandated condition. In the case of 
severe or chronic pain, patients would report their status (i) in 
respect of overall pain status and (ii) pain by body location (e.g., 
thoracic, lumbar, knee) reporting through validated 
instruments pain intensity and functional status. Tracking 
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patients by these validated clinical instruments from baseline 
(i.e., first dispensary visit) would give response to therapy with 
the response reported evaluated in terms of whether it is or is 
not clinically meaningful. Therapy response would also be 
assessed from a subjective assessment perspective using, as 
recommended in the previous commentary, the Patient Global 
Impression of Change (PGIC) instrument 7. Adoption of the PGIC 
not only recognizes the importance of a global validated 
standard of response but a metric that can then be evaluated 
against validated instruments that assess clinical change 
specific to recognized conditions. 
 
Reporting Therapy Response 
From an evidence perspective, the critical issue is to be able to 
capture the product characteristics in terms of a standardized 
measure of THC and/or CBD.  Two options are open: (i) to assess 
response by a cannabinoid THC/CBD using algorithms to create 
a standard measure or (ii) assess response by specific 
cannabinoid products.  While these are not mutually exclusive 
(with the option of reporting on both) the rate limiting step is 
in the information available on the THC/CBD content of the 
various formulations of botanical cannabis: flower, oils and 
concentrates, topicals and edibles, together with the form of 
administration. One issue that legislators should consider is a 
standard label for these various products. Many cannabinoid 
products are mislabeled with little if any quality control of 
presumed ‘same quality’ products in successive production 
batches. It does not seem unreasonable that the manufacturing 
quality controls that are mandated for pharmaceutical products 
should not apply to cannabinoid products. It seems, therefore, 
surprising that legislators would agree to a new condition for 
botanical cannabis without specifying how the THC/CBD and 
form of administration is to be defined for reporting purposes. 
After all, the form of administration, even if there is agreement 
on (say) THC content may impact the effectiveness (if any) of 
the dosing (e.g., impact of sugar content of edibles). An ‘open 
season’ approach is unlikely to meet concerns of providers who 
may be considering botanical cannabis as a therapy option. 
 
Assuming that legislation to support state registries, whether 
dispensary specific or a state-level condition specific registry, 
overcame the issue of a quality controlled, standard measure 
then we could consider reporting options. First, reporting to the 
individual dispensary would give useful feedback on the 
effectiveness of this registry in recommending (presumably) a 
specific product for specified conditions. From a duty of care 
perspective there may be concerns that different products 
(even with similar cannabinoid content) yield a range of 
therapeutic outcomes. Cannabinoid gummy bears may not 
have the therapeutic response of flowers. Questions may also 
be raised, not only against edibles (typically poorly labeled) but 
also for some ‘marginal’ products such as cannabinoid soap or 
bubble bath. Certainly, these may have topical effects (modified 
presumably by the duration of immersion in water) but it is also 
more in the realm of recreational rather than medical 
marijuana. Flower, it should be noted is the more typically 
consumed cannabinoid product (approximately 75% of 
patients) followed by concentrate. In fact, as noted by Stith et 
al, flower appears to provide more symptom relief relative to 
other products with pure indica sub-species providing more 
relief with sativa strains decreasing it. Again, the detail on 
comparing response by condition across product characteristics 
can set the groundwork for evidence-based guidelines relevant 
to dispensary operations, emphasizing that claims for relative 
efficacy of products need to be continually evaluated. 
 
Second, both dispensary specific and state-level dispensaries 
should, as a matter of licensing in the former case, be required 
to submit detailed reports to the state health and legislative 
authorities on response to therapy. With registries in place this 
is low cost and straightforward as reporting can be automated. 
 
Third, reporting to providers. If a provider signs off on a medical 
marijuana card application then, presumably, the provider is 
interested in the response to therapy? Unfortunately, in states 
such as Arizona, provider groups are established simply to 
exploit the demand for cards rather than being involved in any 
management plan for individual patients. They have no interest 
in long-term care or in tracking outcomes for patients. This 
leads the state open to the charge that it has in effect a de facto 
recreational marijuana program. As long as patients can meet 
the requisite assessment fees, then access to dispensaries is 
virtually guaranteed.  It should be made clear by legislators that, 
under the duty of care umbrella, reports should be prepared 
and transmitted to the provider. Third-part intermediaries who 
are solely in the business of facilitating card applications should 
meet standards consistent with a duty of care. Under present 
administrative arrangements, such as Arizona, this is impossible 
unless the patient makes clear the card is issued with the 
knowledge and approval of the provider. All too often 
apparently, the provider is unaware that a medical card has 
been issued. 
 
Care Management 
As emphasized in previous commentaries, dispensary patients 
not only frequently present with more than one authorized 
condition (e.g., severe pain and severe nausea) but also can 
present with a range of other comorbidities. In behavioral 
health practices, for example, it has been suggested that some 
30% of patients present with chronic pain associated with 
conditions such as depression and anxiety. If registries are to 
support a comprehensive data base then there has to be (i) the 
ability to track all conditions reported that are allowed by 
legislation and (ii) to record and, in some instances, capture 
highly prevalent comorbidities. Certainly, the registry should 
capture all conditions reported, together with a list of current 
medical conditions (coded appropriately to ICD-10-CM- 
standards). High prevalence co-morbidities, outside of 
conditions reported, would include: depression, fatigue, 
anxiety and sleep experience.  
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It is important, in those states that have introduced recreational 
marijuana programs (following initiatives for medical 
marijuana) to separate these two markets. One way is to 
enforce rigorous standards for issuing medical marijuana cards 
(e.g., no intermediary provider groups whose sole business is 
initiating the card approval process where, not surprisingly, few 
fail to get approval and pay the requisite fee).   
A second approach would be to encourage those bona fide card 
holders to stay within the medical marijuana market through 
price discrimination: applying higher sales taxes to products 
sold at the recreational marijuana counter (e.g., Colorado). 
 
Conclusions 
This commentary has presented two models for the monitoring 
and evaluation of treatment response for medical marijuana. 
The models presented are potentially complementary: (i)  a 
state-level condition specific registry and (ii) a dispensary 
specific registry.  Both models have their advantages and 
disadvantages. A state-level registry that mandated medical 
marijuana dispensary reporting for specific conditions may well 
run into legislative roadblocks and objections by interest 
groups. The dispensary model faces hurdles in the willingness 
of dispensaries to adopt a registry platform. This may be 
considered an unnecessary impost and one that may undercut 
their financial viability if patients switch to other dispensaries. 
Against this are arguments for a dispensary recognizing it has a 
duty of care; not only to track response to therapy but to 
establish links to providers as an active participant in the 
process of care. This may be driven by self-interest. Given the 
competition for dispensary licenses, a dispensary that has 
established links, offering an evidence-based approach to 
therapy management, may be in pole position for license 
applications and license renewals. After all, the dispensary 
model proposed here is attempting to alleviate the concerns of 
many state legislators that not only is the evidence base thin, 
but that medical marijuana claims are driven by interest groups 
aided by potential licensees. Establishing reporting 
requirements, which may be most attractive to those states 
that are yet to embrace a medical marijuana dispensary model, 
would not only alleviate concerns but also be a major step 
forward in establishing a robust evidence base.  
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